Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

January 10, 2018

Study Completion Date

January 10, 2018

Conditions
Cystic FibrosisMucociliary Clearance Defect
Interventions
OTHER

Baseline (Huff-Cough alone)

"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."

DEVICE

Oscillatory Positive Expiatory Pressure Device

Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.

DEVICE

Whole-Body Vibration Platform

Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.

DEVICE

High Frequency Chest Wall Oscillatory Vest

"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."

Trial Locations (1)

27517

Marsico Clinical Research Center, Chapel Hill

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT03078127 - Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis | Biotech Hunter | Biotech Hunter